Abstract:Introduction Cognitive impairment is prevalent and pronounced among people with schizophrenia (PwS). These individuals experience a large disability and financial burdens. Annually, US costs estimate roughly $87,000 per PwS, largely related to cognitive deficits and associated disability. Risk factors for poor cognition may include older age and female sex. For PwS, illness-specific risks may include severity of positive and negative symptoms, and antipsychotic and anticholinergic use. Thus, our aim is to assess susceptibility and risks in this population in order to target therapy, improve outcomes, enhance quality of life, and lower costs. We hypothesize that poor cognition will be associated with older age and female sex for both non psychiatric comparison (NC) and PwS groups. For PwS, we hypothesize that poor cognition will be associated with more severe positive and negative symptoms, as well as with greater antipsychotic dosage and anticholinergic use. Methods We performed a cross-sectional analysis on 155 participants (51% were female) recruited from the San Diego area via flyering, outreach, and word of mouth. They range between 26 to 65 years of age. Of this sample, 92 participants met the DSM-5 criteria for schizophrenia and schizoaffective disorder, and 63 were non-psychiatric comparison participants with no history of major mental illness. We assessed cognitive impairment using deficit scores, calculated based on performance (age- and sex-normed t-scores) on the MATRICS Consensus Cognitive Battery and Delis-Kaplan Executive Function System (DKEFS) for executive functioning. Domains of cognition assessed were executive functioning, processing speed, attention and vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Schizophrenia symptom severity was assessed using the Scale for Assessment of Positive Symptoms (SAPS) and Scale for Assessment of Negative Symptoms (SANS). For psychiatric medication use, we examined daily dosage of antipsychotics, and whether the participant was taking anticholinergics. Chi-square, t-tests and logistic regressions were used to compare differences between impaired and non-impaired participants within NCs and PwS across all domains of cognition. Results Cognitive impairment was more frequent among PwS compared to NCs across all domains of cognition (Table 1). Among PwS, older age was associated with only processing speed impairment (p = 0.037). Female sex was associated with processing speed impairment (p = 0.018) and verbal memory impairment (p = 0.010) among PwS. Among NCs, older age (p = 0.036) was associated with only verbal memory impairment. In terms of schizophrenia-specific factors, higher antipsychotic dosages were associated with processing speed impairment (p = 0.019) and verbal memory impairment (p = 0.026). Anticholinergic use was associated with social cognitive impairment (p = 0.025). Conclusions Cognitive impairment is more severe and prevalent among PwS than among NCs, and risk factors differ between groups and across domains. Surprisingly, only among NCs was age associated with verbal memory impairment, while among PwS, age was associated with processing speed impairment. PwS have been observed to have both a neurodevelopmental and neurodegenerative pattern of decline, yet there may also be survivor effects where the older PwS in the sample are actually healthier and more cognitively impaired than PwS who did not survive to this age. Female sex was a risk factor for cognitive impairment only among PwS, possibly reflecting effects of sex hormones or sex differences in lifestyle. We found both antipsychotic and anticholinergic relationships with cognitive deficits - which is consistent with the risks associated with both of those medications. While these findings are preliminary, we plan to further investigate the context of our findings, examining key correlates of age and sex on other lifestyle risk factors (sleep, activity, diet) as well as more refined assessments of medication burden in this population. These findings may aid in screening efforts among PwS and guiding medication management to optimize healthy cognitive aging.

Cognitive impairment and C-reactive protein in clinically stable schizophrenia outpatients: a focus on sex differences

Differences in Inflammatory Marker Profiles and Cognitive Functioning Between Deficit and Nondeficit Schizophrenia

Gender Differences of Schizophrenia Patients with and Without Depressive Symptoms in Clinical Characteristics.

Sex Differences in the Association of Treatment-Resistant Schizophrenia and Serum Interleukin-6 Levels

Disturbed sex hormones milieu in males and females with major depressive disorder and low-grade inflammation

Correlations between Immunoinflammatory Factor Levels and Cognitive Functions and Brain Structural Magnetic Resonance Imaging Features among Patients with Primary Schizophrenia

Sex differences in association between cognitive impairment and clinical correlates in Chinese patients with first-episode drug-naïve schizophrenia

Correlation of Serum High-Sensitivity C-Reactive Protein, Homocysteine, and Macrophage Migration Inhibitory Factor Levels With Symptom Severity and Cognitive Function in Patients With Schizophrenia

Immunoinflammatory features and cognitive function in treatment-resistant schizophrenia: unraveling distinct patterns in clozapine-resistant patients

Sex-specific associations between 10-year cardiovascular risk, clinical symptoms and cognitive impairments in schizophrenia

Exploring the relationship between lipid metabolism and cognition in individuals living with stable-phase Schizophrenia: a small cross-sectional study using Olink proteomics analysis

Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function

- Individuals with major depressive disorder and inflammation exhibited sex hormone imbalance: new insights from the Biomarker in Depression (BIODEP) study

Role and Perspectives of Inflammation and C-Reactive Protein (CRP) in Psychosis: An Economic and Widespread Tool for Assessing the Disease

Sex differences between serum total bilirubin levels and cognition in patients with schizophrenia

Association Between Metabolic Risk Factors and Cognitive Impairment in Schizophrenia Based on Sex.

Relationships among Serum C-reactive Protein, Receptor for Advanced Glycation Products, Metabolic Dysfunction, and Cognitive Impairments

Cross-Sectional Analysis of Cognitive Impairments and Associated Risk Factors among People with Schizophrenia

Better understanding of c-reactive protein and leukocytes in psychiatric inpatients with affective disorders: A biopsychosocial approach

Relationship Between Plasma Cytokine Level and Cognitive Function in Patients with Stable Schizophrenia

Peripheral Inflammation is Associated with Impairments of Inhibitory Behavioral Control and Visual Sensorimotor Function in Psychotic Disorders.